Breathtaking Interim Trial Data for Voyager Therapeutics' (VYGR) Gene Therapy in Advanced Parkinson’s Disease
Parkinson’s disease is a neurological disorder that affects movement, muscle control, and balance. Parkinson’s disease most commonly affects people 55 - 75 years old, but it can also develop in younger people. The disease is usually progressive, with symptoms becoming more severe over time.
According to the Parkinson’s Disease Foundation, about 60,000 Americans are diagnosed with Parkinson's disease each year, and this number does not reflect the thousands of cases that go undetected. There are currently no therapies that effectively slow or reverse the progression of Parkinson’s disease.
After the closing bell Wednesday, Voyager Therapeutics, Inc. (Nasdaq:VYGR) said that the interim data from Cohorts 1 and 2 of an ongoing Phase 1b trial at six and twelve months of follow-up in patients with advanced Parkinson’s disease showed that accurate MRI-guided delivery of escalating doses of the company's VY-AADC01 were well tolerated and resulted in increased coverage of the putamen, increased AADC enzyme activity, enhanced response to levodopa, and dose-related, clinically meaningful improvements in various measures of patients’ motor function.
According to Voyager Therapeutics, at 12 months in Cohort 2, treatment with its VY-AADC01 resulted in a 14-point, or 44%, improvement in UPDRS-III off medication, a 9-point, or 55% improvement in UPDRS-III on medication, and a 2.2 hour, or 48%, decrease in diary off-time from baseline.
+ The UPDRS is a standard clinical rating scale for Parkinson’s disease. Part III of this scale measures motor function by physician examination.
Shares of the clinical-stage gene therapy company soared more than 25% in the extended session, following the announcement.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer